USS Investment Management Ltd acquired a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 11,500 shares of the biotechnology company’s stock, valued at approximately $1,324,000.
Other large investors also recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Corcept Therapeutics during the 2nd quarter worth approximately $1,080,964,000. First Trust Advisors LP lifted its holdings in shares of Corcept Therapeutics by 213.5% in the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after acquiring an additional 1,480,059 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics in the 2nd quarter valued at approximately $49,185,000. Bank of America Corp DE bought a new stake in shares of Corcept Therapeutics during the 2nd quarter valued at approximately $28,569,000. Finally, Legal & General Group Plc acquired a new position in Corcept Therapeutics during the 2nd quarter worth approximately $18,962,000. 93.61% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, Director Kimberly Park sold 26,685 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $122.55, for a total transaction of $3,270,246.75. Following the completion of the sale, the director owned 30,000 shares in the company, valued at $3,676,500. The trade was a 47.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director James Wilson sold 10,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $110.69, for a total transaction of $1,106,900.00. Following the completion of the sale, the director directly owned 1,064,543 shares of the company’s stock, valued at approximately $117,834,264.67. The trade was a 0.93% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 259,435 shares of company stock valued at $28,492,179. 20.70% of the stock is currently owned by corporate insiders.
Corcept Therapeutics Stock Down 2.2%
Shares of NASDAQ CORT opened at $63.56 on Friday. The firm has a fifty day simple moving average of $99.03 and a 200 day simple moving average of $77.05. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $126.38. The company has a market capitalization of $6.96 billion, a PE ratio of 50.05 and a beta of 0.54.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.84 by $0.17. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. The business had revenue of $340.47 million during the quarter, compared to analysts’ expectations of $339.12 million. During the same quarter last year, the firm posted $0.16 earnings per share. The firm’s revenue was up 64.0% on a year-over-year basis. As a group, equities analysts expect that Corcept Therapeutics Incorporated will post 1.97 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on CORT. Canaccord Genuity Group increased their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Zacks Research lowered Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Weiss Ratings upgraded shares of Corcept Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday. Wall Street Zen upgraded shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Finally, HC Wainwright reissued a “buy” rating and set a $165.00 target price on shares of Corcept Therapeutics in a report on Friday, September 18th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Corcept Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $139.50.
Check Out Our Latest Stock Analysis on Corcept Therapeutics
About Corcept Therapeutics
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Read More
- Five stocks we like better than Corcept Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
